Applied Genetic Technologies intends to sell 3.57M shares at a price of $13-15 in its Nasdaq IPO.
At $14, Applied Genetic would raise a net $44.8M.
The company, which develops gene therapy for inherited retinal disease, plans to trade under the ticker symbol "AGTC."
There's also a greenshoe option of 535,650 shares. (S-1)